Pasar al contenido principal

VALIDACION DE UNA NUEVA SUBFAMILIA DE QUINASAS DEPENDIENTES DE CICLINA COMO DIANAS TERAPEUTICAS EN CANCER

RTI2018-095582-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Squamous differentiation requires G2/mitosis slippage to avoid apoptosis

  • Sanz-Gómez, Natalia
  • Pedro, Isabel de
  • Ortigosa, Beatriz
  • Santamaría, David
  • Malumbres, Marcos
  • Cárcer, Guillermo de
  • Gandarillas, Alberto
The cellular mechanisms controlling cell fate in self-renewal tissues remain unclear. Cell cycle failure often leads to an apoptosis anti-oncogenic response. We have inactivated Cdk1 or Polo-like-1 kinases, essential targets of the mitotic checkpoints, in the epithelia of skin and oral mucosa. Here, we show that inactivation of the mitotic kinases leading to polyploidy in vivo, produces a fully differentiated epithelium. Cells within the basal layer aberrantly differentiate and contain large or various nuclei. Freshly isolated KO cells were also differentiated and polyploid. However, sustained metaphase arrest downstream of the spindle anaphase checkpoint (SAC) due to abrogation of CDC20 (essential cofactor of anaphase-promoting complex), impaired squamous differentiation and resulted in apoptosis. Therefore, upon prolonged arrest keratinocytes need to slip beyond G2 or mitosis in order to initiate differentiation. The results altogether demonstrate that mitotic checkpoints drive squamous cell fate towards differentiation or apoptosis in response to genetic damage., The work was funded by grants ISCIII-FIS/FEDER PI14/00900 and PI17/01307 (AG), AEI-MICIU/FEDER RTI2018-095582-B-I00 and Programa iLUNG Comunidad de Madrid B2017/BMD-3884 (MM), Asociación Española Contra el Cáncer (AECC) LABAE16017DECA and MCIU/AEI/FEDER RTI2018-095496-B-100 (GdC). NS was recipient of a Universidad de Cantabria/IDIVAL predoctoral fellowship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic interaction between PLK1 and downstream MCPH proteins in the control of centrosome asymmetry and cell fate during neural progenitor division

  • González-Martínez, José
  • Cwetsch, Andrzej W.
  • Gilabert-Juan, Javier
  • Gómez, Jesús
  • Garaulet, Guillermo
  • Schneider, Paulina
  • Cárcer, Guillermo de
  • Mulero, Francisca
  • Caleiras, Eduardo
  • Megías, Diego
  • Porlan, Eva
  • Malumbres, Marcos
Alteration of centrosome function and dynamics results in major defects during chromosome segregation and is associated with primary autosomal microcephaly (MCPH). Despite the knowledge accumulated in the last few years, why some centrosomal defects specifically affect neural progenitors is not clear. We describe here that the centrosomal kinase PLK1 controls centrosome asymmetry and cell fate in neural progenitors during development. Gain- or loss-of-function mutations in Plk1, as well as deficiencies in the MCPH genes Cdk5rap2 (MCPH3) and Cep135 (MCPH8), lead to abnormal asymmetry in the centrosomes carrying the mother and daughter centriole in neural progenitors. However, whereas loss of MCPH proteins leads to increased centrosome asymmetry and microcephaly, deficient PLK1 activity results in reduced asymmetry and increased expansion of neural progenitors and cortical growth during mid-gestation. The combination of PLK1 and MCPH mutations results in increased microcephaly accompanied by more aggressive centrosomal and mitotic abnormalities. In addition to highlighting the delicate balance in the level and activity of centrosomal regulators, these data suggest that human PLK1, which maps to 16p12.1, may contribute to the neurodevelopmental defects associated with 16p11.2–p12.2 microdeletions and microduplications in children with developmental delay and dysmorphic features., JGM and DMA received predoctoral contracts from the Ministry of Education of Spain (FPI grant BES-2016-077901). This work was supported by Grant PID2019-104763RB-I00 and Ramón y Cajal contract (RYC-2014-15991), both from MINECO/AEI/FEDER (EU) to EP; and grants from the European Commission Seventh Framework Programme (ERA-NET NEURON8-Full-815-094), AEI-MICIU/FEDER (RTI2018-095582-B-I00 and RED2018-102723- T), and the iLUNG programme from the Comunidad de Madrid (B2017/BMD-3884) to MM. CNIO is a Severo Ochoa Center of Excellence (AEI-MICIU CEX2019-000891-S).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner

  • Sanz-Castillo, Belén
  • Hurtado, Begoña
  • Vara-Ciruelos, Diana
  • El Bakkali, Aicha
  • Hermida, Dario
  • Salvador-Barbero, Beatriz
  • Martínez-Alonso, Diego
  • González-Martínez, José
  • Santiveri, Clara
  • Campos-Olivas, Ramón
  • Ximénez de Embún, Pilar
  • Redondo-Muñoz, Javier
  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
The AKT-mTOR pathway is a central regulator of cell growth and metabolism. Upon sustained mTOR activity, AKT activity is attenuated by a feedback loop that restrains upstream signaling. However, how cells control the signals that limit AKT activity is not fully understood. Here, we show that MASTL/Greatwall, a cell cycle kinase that supports mitosis by phosphorylating the PP2A/B55 inhibitors ENSA/ARPP19, inhibits PI3K-AKT activity by sustaining mTORC1- and S6K1-dependent phosphorylation of IRS1 and GRB10. Genetic depletion of MASTL results in an inefficient feedback loop and AKT hyperactivity. These defects are rescued by the expression of phosphomimetic ENSA/ARPP19 or inhibition of PP2A/B55 phosphatases. MASTL is directly phosphorylated by mTORC1, thereby limiting the PP2A/B55-dependent dephosphorylation of IRS1 and GRB10 downstream of mTORC1. Downregulation of MASTL results in increased glucose uptake in vitro and increased glucose tolerance in adult mice, suggesting the relevance of the MASTL-PP2A/B55 kinase-phosphatase module in controlling AKT and maintaining metabolic homeostasis., BS‐C was supported by Foundation la Caixa, and AEB was funded by Comunidad de Madrid. MÁ‐F was supported by a young investigator grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2014‐60442‐JIN; co‐financed by FEDER funds). The Cell Division and Cancer lab of the CNIO is supported by grants from the MICIU (RTI2018‐095582‐B‐I00), Red de Excelencia iDIFFER (RED2018‐102723‐T), Comunidad de Madrid (B2017/BMD‐3884), and Worldwide Cancer Research (WCR‐20‐0155)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

  • Salvador-Barbero, Beatriz
  • Álvarez-Fernández, Mónica
  • Zapatero-Solana, Elisabet
  • Bakkali, Aicha El
  • Camino Menéndez, María del
  • López-Casas, Pedro P.
  • Domenico, Tomas Di
  • Xie, Tao
  • VanArsdale, Todd
  • Shields, David J.
  • Hidalgo, Manuel M.
  • Malumbres, Marcos
Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or antimitotic chemotherapies as the former prevent cell-cycle entry, thus interfering with S-phase- or mitosis-targeting agents. Here, we report that sequential administration of CDK4/6 inhibitors after taxanes cooperates to prevent cellular proliferation in pancreatic ductal adenocarcinoma (PDAC) cells, patient-derived xenografts, and genetically engineered mice with Kras G12V and Cdkn2a-null mutations frequently observed in PDAC. This effect correlates with the repressive activity of CDK4/6 inhibitors on homologous recombination proteins required for the recovery from chromosomal damage. CDK4/6 inhibitors also prevent recovery from multiple DNA-damaging agents, suggesting broad applicability for their sequential administration after available chemotherapeutic agents., M.Á.-F. received young investigator grants from MINECO (SAF2014-60442-JIN, cofinanced by FEDER funds) and the Asociación Española contra el Cancer (AECC). The laboratory of M.M. is supported by grants from MICIU [SAF2015-69920-R and RTI2018-095582-B-I00 (AEI-MICIU/FEDER, UE)], and the iLUNG program from the Comunidad de Madrid (B2017/BMD-3884). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers., MAF received young investigator grants from MINECO (SAF2014-60442-JIN, co-financed by FEDER funds) and the Asociación Española contra el Cancer (AECC). The laboratory of M.M. is supported by grants from AEI-MICIU/FEDER (RTI2018-095582-B-I00 and RED2018-102723-T), and the iLUNG program from the Comunidad de Madrid (B2017/BMD-3884). CNIO is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transient exposure to miR‐203 enhances the differentiation capacity of established pluripotent stem cells

  • Salazar‐Roa, María
  • Trakala, Marianna
  • Álvarez-Fernández, Mónica
  • Valdés‐Mora, Fátima
  • Zhong, Cuiqing
  • Muñoz, Jaime
  • Yu, Yang
  • Peters, Timothy J.
  • Graña‐Castro, Osvaldo
  • Serrano, Rosa
  • Zapatero-Solana, Elisabet
  • Abad, María
  • Bueno, María José
  • Gómez de Cedrón, Marta
  • Fernández-Piqueras, José
  • Serrano, Manuel
  • Blasco, María A.
  • Wang, Da‐Zhi
  • Clark, Susan J.
  • Izpisua‐Belmonte, Juan Carlos
  • Ortega, Sagrario
  • Malumbres, Marcos
Full differentiation potential along with self‐renewal capacity is a major property of pluripotent stem cells (PSCs). However, the differentiation capacity frequently decreases during expansion of PSCs in vitro. We show here that transient exposure to a single microRNA, expressed at early stages during normal development, improves the differentiation capacity of already‐established murine and human PSCs. Short exposure to miR‐203 in PSCs (miPSCs) induces a transient expression of 2C markers that later results in expanded differentiation potency to multiple lineages, as well as improved efficiency in tetraploid complementation and human–mouse interspecies chimerism assays. Mechanistically, these effects are at least partially mediated by direct repression of de novo DNA methyltransferases Dnmt3a and Dnmt3b, leading to transient and reversible erasure of DNA methylation. These data support the use of transient exposure to miR‐203 as a versatile method to reset the epigenetic memory in PSCs, and improve their effectiveness in regenerative medicine., M.S.R. was supported by the Asociación Española contra el Cáncer (AECC; 2012 AIOA120833SALA and 2018 INVES18005SALA) and a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU). M.T. was supported by Fundación La Caixa. M.A.F. was supported by MICIU (SAF2014‐60442‐JIN). J.F.P. was funded by MICIU (RTI2018‐093330‐B/FEDER‐EU), Ramón Areces Foundation (CIVP19S7917), CAM (B2017/BMD‐3778), and AECC (2018, PROYE18054PIRI). F.V.M was supported by the National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. Work in S.J.C laboratory was supported by the National Health and Medical Research Council (NHMRC 1063560). M.A.B. laboratory is funded by SAF2013‐45111‐R from MICIU, Fundación Botín and Banco Santander, and Worldwide Cancer Research (WCR16‐1177). Work in S.O. laboratory was funded by MICIU grant (SAF2013‐44866‐R). Work in the M.M. laboratory was supported by grants from the MICIU (RTI2018‐095582‐B‐I00, RED2018‐102723‐T, and SAF2017‐92729‐EXP), and the iLUNG Programme (B2017/BMD‐3884) from the Comunidad de Madrid. The CNIO is a Severo Ochoa Centers of Excellence (MICIU award SEV‐2015‐0510)., Peer reviewed